Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CD154 (CD40 Ligand) Monoclonal Antibody (MR1), PE-eFluor™ 610, eBioscience™, Invitrogen™
Armenian Hamster Monoclonal Antibody
Supplier: Invitrogen™ 61154180

Description
CD40 Ligand (CD40-L), or CD154, is a membrane glycoprotein and differentiation antigen expressed on the surface of T cells. The CD40 Ligand stimulates B cell proliferation and secretion of all immunoglobulin isotypes in the presence of cytokines. CD40 Ligand has been shown to induce cytokine production and tumoricidal activity in peripheral blood monocytes. It also co-stimulates proliferation of activated T cells and this is accompanied by the production of IFN-gamma, TNF-alpha, and IL-2.
Specifications
CD154 (CD40 Ligand) | |
Monoclonal | |
0.2 mg/mL | |
PBS with 0.09% sodium azide; pH 7.2 | |
P27548 | |
CD40LG | |
Affinity chromatography | |
RUO | |
21947 | |
4°C, store in dark, DO NOT FREEZE! | |
Liquid |
Flow Cytometry | |
MR1 | |
PE-eFluor 610 | |
CD40LG | |
CD154; CD40 antigen ligand; CD40 ligand; CD40 ligand CD154; CD40 ligand, membrane form; CD40 ligand, soluble form; CD40L; CD40-L; Cd40lg; gp39; hCD40L; H-CD-40-L; HIGM1; IGM; IMD3; Ly62; Ly-62; M-CD-40-L; RP23-153G22.3; T-B cell-activating molecule; T-BAM; T-cell antigen Gp39; TNF-related activation protein; TNFSF5; TRAP; tumor necrosis factor (ligand) superfamily member 5; tumor necrosis factor (ligand) superfamily, member 5; tumor necrosis factor ligand superfamily member 5 | |
Armenian Hamster | |
25 μg | |
Primary | |
Mouse | |
Antibody | |
IgG |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction